Download PDF

1. Company Snapshot

1.a. Company Description

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems.


In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services.It serves biopharma/pharma, animal health, and human reproductive medicine markets.The company was founded in 1999 and is headquartered in Brentwood, Tennessee.

Show Full description

1.b. Last Insights on CYRX

The recent earnings release of Cryoport, Inc. revealed a loss of $0.42 per share in Q4 2024, surpassing the Zacks Consensus Estimate of a loss of $0.33. While revenue of $228.4 million aligned with company guidance, the commercial cell & gene therapy revenue rose 20% year-over-year. However, the company's high medical care ratios and increasing costs may have contributed to the loss, despite a record number of 701 global clinical trials supported.

1.c. Company Highlights

2. Cryoport's Q3 2025 Earnings: Strong Momentum in Life Sciences Services

In the third quarter, Cryoport reported strong financial performance, with total revenue from continuing operations growing to support its expanding Life Sciences Services and Products segments. The company's Life Sciences Services segment, a key driver of future growth, saw a 16% year-over-year increase, driven in part by a 36% growth in revenue from commercial cell and gene therapy support, reaching $8.3 million. Revenue for the quarter represented a significant step towards the company's updated full-year 2025 outlook of $170 million to $174 million. Adjusted EBITDA loss narrowed to $600,000, indicating progress toward profitability. The actual EPS loss was $0.18, beating estimates of a $0.23 loss.

Publication Date: Nov -23

📋 Highlights
  • Revenue Growth in Core Segments: Double-digit growth in Life Sciences Services (+16% YoY) and Life Sciences Products, driven by 36% YoY increase in commercial cell and gene therapy support to $8.3M.
  • Full-Year Revenue Guidance Raised: Updated 2025 revenue outlook to $170–$174M from continuing operations, reflecting strong momentum in clinical and commercial markets.
  • Product Innovation Launched: MVE Biological Solutions introduced redesigned SC4/2V and SC4/3V vapor shippers for enhanced shipment protection, expanding the product portfolio.
  • Strategic Facility Expansion: Planning a $2026 H2 global supply chain center in Santa Ana, CA, consolidating three locations to optimize operations and client support.
  • EBITDA Pathway to Profitability: Adjusted EBITDA loss narrowed to $0.6M in Q3 2025, with management targeting positive adjusted EBITDA by Q4 2025 or early 2026.

Segment Performance

The company's Life Sciences Services segment continued to be a significant growth driver, with revenue increasing 16% year-over-year. This growth was largely driven by the support of commercial cell and gene therapies, which saw a 36% year-over-year increase. The BioStorage Bioservices revenue also saw a significant 21% increase, contributing to the overall growth in the Life Sciences Services segment.

Guidance and Outlook

Cryoport updated its full-year 2025 outlook for total revenue from continuing operations to the range of $170 million to $174 million. The guidance implies a sequential decline in revenues, which the company attributes to macro uncertainties, including the government shutdown and changing tariff landscape. Management believes this guidance is responsible, balancing the momentum seen in the business against these uncertainties. For 2026, analysts estimate revenue growth at 9.2%, and Jerrell Shelton mentioned that a high single-digit growth rate is a fair assumption.

Valuation

With a P/S Ratio of 2.31, Cryoport's valuation reflects its growth prospects. The EV/EBITDA ratio stands at -27.05, indicating that the company's current valuation is heavily dependent on its future growth prospects. The ROE of 14.78% is a positive indicator of the company's ability to generate returns on equity. As the company moves towards profitability, these valuation metrics will be important to monitor.

Path to Profitability

Robert Stefanovich mentioned that the company is getting very close to crossing the line to positive adjusted EBITDA, and Jerrell Shelton added that they think possibly they can get there in the fourth quarter and certainly early next year. The company is driving utilization of its existing footprint, which will ultimately drive gross margins. With gross margins reaching 48% and even higher on the service side, the company is targeting 55% gross margins overall and a 30% EBITDA margin.

3. NewsRoom

Card image cap

Cryoport: Picks And Shovels For The Gene Therapy Boom

Dec -02

Source: seekingalpha.com

Card image cap

CryoPort, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Analysts

Nov -18

Source: defenseworld.net

Card image cap

Acadian Asset Management LLC Purchases 69,147 Shares of CryoPort, Inc. $CYRX

Nov -14

Source: defenseworld.net

Card image cap

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Nov -06

Source: globenewswire.com

Card image cap

Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript

Nov -05

Source: seekingalpha.com

Card image cap

CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates

Nov -04

Source: zacks.com

Card image cap

Cryoport Reports Strong Q3 Results, Raises FY25 Outlook

Nov -04

Source: benzinga.com

Card image cap

Cryoport Reports Third Quarter 2025 Financial Results

Nov -04

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.96%)

6. Segments

Biopharma/Pharma

Expected Growth: 8%

Cryoport's 8% growth in Biopharma/Pharma is driven by increasing demand for cell and gene therapies, expansion of clinical trials, and rising adoption of cryogenic logistics. Additionally, growing partnerships with pharmaceutical companies, increasing regulatory approvals, and investments in digital platforms are contributing to the segment's growth.

Animal Health

Expected Growth: 7%

Cryoport's Animal Health segment growth is driven by increasing demand for biologics and regenerative medicine, expansion of existing customer relationships, and strategic partnerships. The growing need for temperature-controlled logistics in animal health research and commercialization also contributes to this 7% growth.

Human Reproductive Medicine

Expected Growth: 10%

Cryoport's Human Reproductive Medicine segment growth is driven by increasing demand for fertility treatments, advancements in cryopreservation technology, and strategic partnerships with leading fertility clinics. Additionally, growing awareness of egg and sperm freezing, coupled with an aging population, fuels the need for reliable cryogenic logistics solutions, propelling Cryoport's 10% growth.

7. Detailed Products

Cryoport Express

A portable, dry vapor shipper that uses liquid nitrogen to maintain extremely low temperatures during transportation

Cryoport Express 3

A high-performance, dry vapor shipper designed for the transportation of high-value, temperature-sensitive materials

Cryopack 3

A high-performance, dry vapor shipping system designed for the transportation of high-value, temperature-sensitive materials

Cryologics

A cloud-based logistics platform that provides real-time monitoring and tracking of temperature-sensitive shipments

Cryoportal

A cloud-based platform that provides real-time monitoring and tracking of temperature-sensitive shipments, as well as data analytics and reporting

Cryogenic Storage

A cryogenic storage service that provides secure, temperature-controlled storage for biological samples and other temperature-sensitive materials

8. Cryoport, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Cryoport's cryogenic logistics services are highly specialized and there are limited substitutes available, reducing the threat of substitutes.

Bargaining Power Of Customers

Cryoport's customers, such as pharmaceutical and biotechnology companies, have some bargaining power due to their large orders, but Cryoport's specialized services and strong relationships mitigate this power.

Bargaining Power Of Suppliers

Cryoport has a diversified supplier base and is not heavily dependent on a single supplier, reducing the bargaining power of suppliers.

Threat Of New Entrants

The cryogenic logistics industry has low barriers to entry, and new entrants could potentially disrupt Cryoport's market share, especially with the increasing demand for cryogenic logistics services.

Intensity Of Rivalry

The cryogenic logistics industry is moderately competitive, with a few established players, but Cryoport's strong brand reputation and specialized services help to differentiate it from competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 44.09%
Debt Cost 3.95%
Equity Weight 55.91%
Equity Cost 11.93%
WACC 8.41%
Leverage 78.87%

11. Quality Control: Cryoport, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Pitney Bowes

A-Score: 5.3/10

Value: 7.3

Growth: 1.0

Quality: 4.9

Yield: 6.0

Momentum: 9.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Napco Security Technologies

A-Score: 5.0/10

Value: 1.2

Growth: 8.8

Quality: 8.6

Yield: 1.0

Momentum: 6.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Cryoport

A-Score: 4.6/10

Value: 8.3

Growth: 3.9

Quality: 6.8

Yield: 0.0

Momentum: 7.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Air T

A-Score: 4.6/10

Value: 8.2

Growth: 5.4

Quality: 3.2

Yield: 0.0

Momentum: 8.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Radiant Logistics

A-Score: 4.0/10

Value: 5.8

Growth: 4.0

Quality: 4.6

Yield: 0.0

Momentum: 3.0

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Forward Air

A-Score: 2.3/10

Value: 6.2

Growth: 2.4

Quality: 1.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.49$

Current Price

9.49$

Potential

-0.00%

Expected Cash-Flows